Coffee and In-vivo Oxidative Stress

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

180 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-03-31

Study Completion Date

2010-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Food and beverage intake that leads to a decrease in the level of in vivo markers of oxidative stress indicates that such foods and beverages act as antioxidants (AOX) in humans. Coffee drinking at a high level (\> 900 ml/day) for a short period of time (1 week) has been shown to reduce DNA oxidative damage-as indicated by a decrease in the level of percent tail DNA (%T)- in study populations comprised mainly of young adults aged \< 30 years. It is not clear whether such findings remain present over a longer period of time, and to extend such findings across a population that is more representative of European adults who consume common daily intakes of coffee, which is a low-to-moderate daily intake level (\< 750 ml/day). As such, the investigators propose to determine the effect of drinking 3 and 5 cups of coffee per day (equivalent to 450 and 750 ml per day, respectively) for 8-weeks on markers of in vivo oxidative stress relative to control in a population of healthy adults free of chronic diseases aged 35 to 65 years. To ensure that overall health is considered, the investigators will also evaluate the effect on markers of cardiovascular health, inflammation, and glycemic control.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Coffee, Exercise, and Oxidative Stress

NCT01832701

Healthy

COMPLETED NA

Dose Response Bioavailability of Coffee and Green Tea Antioxidants in Humans

NCT01089920

Healthy

COMPLETED NA

Green Coffee Extract Supplementation and Oxidative Stress, Systemic and Vascular Inflammation

NCT03265184

Metabolic Syndrome

COMPLETED NA

Coffee Polyphenols Antioxidants

NCT01832662

Healthy

COMPLETED NA

Bioavailability of Chlorogenic and Phenolic Acids From Soluble Coffees

NCT01400386

Healthy

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Objective: The main objective of the present study is to determine the short- and mid-term effects of a coffee, on oxidative stress parameters in humans.

Study design: randomized, placebo-controlled, investigator-blinded, 3-arm parallel Study population: 168 apparently healthy volunteers: males and females aged \>=35 and \<= 65 years.

Intervention: The treatments consist of daily consumption of either:

Treatment 1: 0.45 L coffee (3 cups) and 0.30 L bottled water daily or; Treatment 2: 0.75 L coffee (5 cups) daily or; Treatment 3: 0.75 L water daily Duration of the treatment intervention is 8 weeks. Before the intervention period starts, a run-in period of five weeks where all subjects maintain their low antioxidant diet (Dutch average) is conducted by all subjects in order to standardize the antioxidant intake of the subjects.

Main study parameters/endpoints: Mean level of %T as a measure of DNA oxidative damage at week 8. Secondary outcome is the mean level of 8-isoprostane in 24 hr urine.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

low coffee dose

3 cups of coffee daily for 8 weeks

Group Type EXPERIMENTAL

Coffee consumption

Intervention Type DIETARY_SUPPLEMENT

3 or 5 cups of coffee daily for eight weeks

high coffee dose

5 cups of coffee daily for eight weeks

Group Type EXPERIMENTAL

Coffee consumption

Intervention Type DIETARY_SUPPLEMENT

3 or 5 cups of coffee daily for eight weeks

Control

Consumption of water instead of coffee daily for eight weeks

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Coffee consumption

3 or 5 cups of coffee daily for eight weeks

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy as assessed by the

* health and lifestyle questionnaire, (P8353 F02; in Dutch)
* results of the pre-study laboratory tests
2. Males and females aged \>= 35 and \<= 65 years at Week 01 of the study
3. Body Mass Index (BMI) \>= 20.0 but \<= 34.9 kg/m2
4. Blood pressure (automated measurement at site): systolic blood pressure \<= 139 mm Hg and diastolic blood pressure \<= 89 mm Hg
5. Fasting glucose \<= 6.9 mmol/L
6. No smoking or moderate smoking of 1 to 19 cigarettes per day, with the proportion of smokers and nonsmokers representative of the European adult population aged 35-65 years
7. Normal European eating habits as assessed by P8353 F02. Fruit and vegetable consumption at a level representative or less for the European population as assessed by P8353 F06
8. Habitual caffeinated coffee drinker who consumes \> 1 cup per day on at least 5 days per week as assessed by P8353 F02
9. Voluntary participation
10. Having given written informed consent
11. Willing to comply with the study procedures
12. Willing to accept use of all nameless data, including publication, and the confidential use and storage of all data for at least 15 years
13. Willing to accept the disclosure of the financial benefit of participation in the study to the authorities concerned.

Exclusion Criteria

Subjects with one or more of the following characteristics will be excluded from participation:

1. Participation in any clinical trial including blood sampling and/or administration of substances up to 90 days before Day 01 of this study
2. Participation in any non-invasive clinical trial up to 30 days before Day 01 of this study, including no blood sampling and/or oral, intravenous, inhalatory administration of substances
3. Having a history of medical or surgical events that may significantly affect the study outcome (including cardiovascular disease or hypertension at repeated measurements, hypercholesterolemia, hyperglycaemia, kidney or liver disease, cancer, mental illness) based on the health questionnaire
4. Hypertension as indicated by a systolic BP \>= 140 mm Hg or a diastolic BP \>= 90 mm Hg
5. Hypercholesterolemia as indicated by a fasting LDL-cholesterol \>= 4.9 mmol/L at a single screening visit or the use of anti-hypercholesterolemia drugs
6. Diabetes as indicated by a fasting blood glucose \>= 7.0 mmol/L at a single screening visit
7. Having (a history of) (severe) gastro-intestinal complaints
8. Using medication for high blood pressure, high cholesterol level, gastro-intestinal complaints, or antidepressants. With the exception of medication for heartburn
9. Not willing to give up the use of coffee, tea, dark chocolate (and foods/beverages containing dark chocolate), vitamin supplements, mineral supplements, herbal products (food, beverage, or supplements), antioxidant dietary supplements, omega-3 fatty acid supplements including flaxseed oil and fish oil supplements, red wine or rose wines, port, sherry, or specific fortified foods
10. Not willing to give up the consumption of coffee beans as food or in foods or the consumption of coffee or espresso in foods (e.g. Tiramisu)
11. The use of any non-study caffeinated/decaffeinated coffee beverage or caffeinated/decaffeinated espresso-based beverage (espresso, cappuccino, latte, frappuccino, or frappe
12. Alcohol consumption \> 28 units/week for males and \> 21 units/week for females
13. Eating lots of fruit and vegetables (i.e. more than 400 gram vegetables per day and more than 4 servings of fruit per day at screening and during the study. This is twice that of the Dutch dietary recommendations for fruit and vegetable intake)
14. Changing smoking habits (\> 5 cigarettes per day)
15. Exercising heavily (\> 7 hours/week)
16. Not willing to give up supplement (antioxidant containing) use (to be specified)
17. Reported unexplained weight loss or gain of \> 2 kg in the month prior to the pre-study screening
18. Reported slimming or medically prescribed diet
19. Reported vegan, vegetarian or macrobiotic
20. Recent blood donation (\<1 month prior to the start of the study)
21. Not willing to give up blood donation during the study.
22. Pregnant or lactating or wishing to become pregnant in the period of the study
23. Personnel of TNO Quality of Life, their partner and their first and second degree relatives
24. Not having a general practitioner
25. Not willing to accept information-transfer concerning participation in the study, or information regarding his/her health, like laboratory results, findings at anamnesis or physical examination and eventual adverse events to and from his general practitioner.

Minimum Eligible Age

35 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes